. | Any CS use (n) . | Systemic CS use (n) . | Local CS use (n) . |
---|---|---|---|
No CS use at T1 or T2 | 61 937 (76%) | ||
CS use at either T1 or T2 | 19 424 | 2351 | 18 292 |
Discontinuation at follow-up | 5540 (7%) | 372 | 5448 |
New CS use | 8867 (11%) | 1812 | 8130 |
CS use at both T1 and T2 | 5017 (6%) | 167 | 4714 |
. | Any CS use (n) . | Systemic CS use (n) . | Local CS use (n) . |
---|---|---|---|
No CS use at T1 or T2 | 61 937 (76%) | ||
CS use at either T1 or T2 | 19 424 | 2351 | 18 292 |
Discontinuation at follow-up | 5540 (7%) | 372 | 5448 |
New CS use | 8867 (11%) | 1812 | 8130 |
CS use at both T1 and T2 | 5017 (6%) | 167 | 4714 |
“Any CS use”: either systemic CS use or local CS use.
“Discontinuation at follow-up”: CS use reported at T1, but not at T2.
“New CS use”: CS use only reported at T2, not at T1.
Abbreviations: CS, corticosteroid; T1, baseline assessment; T2, second assessment.
. | Any CS use (n) . | Systemic CS use (n) . | Local CS use (n) . |
---|---|---|---|
No CS use at T1 or T2 | 61 937 (76%) | ||
CS use at either T1 or T2 | 19 424 | 2351 | 18 292 |
Discontinuation at follow-up | 5540 (7%) | 372 | 5448 |
New CS use | 8867 (11%) | 1812 | 8130 |
CS use at both T1 and T2 | 5017 (6%) | 167 | 4714 |
. | Any CS use (n) . | Systemic CS use (n) . | Local CS use (n) . |
---|---|---|---|
No CS use at T1 or T2 | 61 937 (76%) | ||
CS use at either T1 or T2 | 19 424 | 2351 | 18 292 |
Discontinuation at follow-up | 5540 (7%) | 372 | 5448 |
New CS use | 8867 (11%) | 1812 | 8130 |
CS use at both T1 and T2 | 5017 (6%) | 167 | 4714 |
“Any CS use”: either systemic CS use or local CS use.
“Discontinuation at follow-up”: CS use reported at T1, but not at T2.
“New CS use”: CS use only reported at T2, not at T1.
Abbreviations: CS, corticosteroid; T1, baseline assessment; T2, second assessment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.